Fuji Pharma Co., Ltd.
Stock Price Chart
2026/10/09 12:26 UpdatedPrice Trend
2026/10/09 12:26 UpdatedPrice & Trading Details
2026/10/09 12:26 UpdatedPRICE
TRADING
Analyst Recommendations 2 analysts
Updated 2026/10/01Shareholder Composition
Updated 2026/10/01Dividend History 4Years Growth
Updated 2026/10/04| Year | Dividend | Change |
|---|---|---|
| 2026 | ¥49 | +7.7% |
| 2025 | ¥46 | +7.1% |
| 2024 | ¥43 | +14.9% |
| 2023 | ¥37 | +5.7% |
| 2022 | ¥35 | - |
Financial Performance
2026/10/04 UpdatedRevenue & Profit
Margins
Cash Flow
Financial Health
| 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|
| Income Statement | ||||
| Revenue | ¥35,426M | ¥40,889M | ¥46,138M | ¥51,677M |
| Gross Profit | ¥14,558M | ¥16,514M | ¥17,844M | ¥20,763M |
| Operating Income | ¥3,781M | ¥3,862M | ¥3,883M | ¥4,994M |
| Pretax Income | ¥3,800M | ¥4,506M | ¥8,472M | ¥4,330M |
| Net Income | ¥2,696M | ¥3,435M | ¥6,146M | ¥3,000M |
| EPS | ¥111.01 | ¥141.37 | ¥252.85 | ¥122.94 |
| Operating Margin | 10.67% | 9.45% | 8.42% | 9.66% |
| Balance Sheet | ||||
| Total Assets | ¥75,538M | ¥85,332M | ¥90,000M | ¥93,405M |
| Total Equity | ¥35,801M | ¥41,172M | ¥45,558M | ¥46,902M |
| Total Liabilities | ¥39,737M | ¥44,160M | ¥44,442M | ¥46,503M |
| Cash | ¥3,546M | ¥2,324M | ¥4,585M | ¥7,245M |
| Interest-bearing Debt | ¥24,569M | ¥28,948M | ¥29,254M | ¥30,937M |
| Equity Ratio | 47.39% | 48.25% | 50.62% | 50.21% |
| D/E Ratio | 0.69 | 0.70 | 0.64 | 0.66 |
| Cash Flow | ||||
| Operating CF | -¥658M | ¥1,917M | ¥4,151M | ¥5,801M |
| Investing CF | -¥11,271M | -¥5,240M | -¥1,658M | -¥4,219M |
| Financing CF | ¥5,094M | ¥1,915M | -¥435M | ¥954M |
| Free CF | -¥13,081M | -¥1,980M | -¥221M | ¥1,947M |
| Efficiency | ||||
| ROE | 7.53% | 8.34% | 13.49% | 6.40% |
| ROA | 3.57% | 4.03% | 6.83% | 3.21% |
Latest IR Information
-
Q3 Financial Summary for the Fiscal Year Ending September 2026 [Japanese GAAP] (Consolidated)
This quarter's consolidated results disclose trends in net sales and profits, segment contributions, and shifts in financial position. It describes progress under the long-term plan 'Growth and Contribution,' the status of product portfolio strengthening, and R&D investment progress.
Read more -
FY2026 September Quarter (Second Quarter) Financial Summary [Japanese Standards] (Consolidated)
For the second quarter of FY2026, net sales were 297.16 billion yen (up 23.3% YoY), and operating profit was 4.39 billion yen (up 90.8% YoY).
Read more -
[Fuji Pharmaceutical Industries] Recognition of Securities Evaluation Loss and Future Outlook | FY2026 September
Fuji Pharmaceutical Industries recorded an securities evaluation loss of ¥3,519 million in the second quarter of FY2026 September. There has been no change to the consolidated earnings forecast for this term, and the company reported a loss due to the...
Read more -
Notice on Revision of Interim Dividend Forecast for the Fiscal Year Ending September 2026 (62nd Term)
The interim dividend forecast for the fiscal year ending September 2026 has been revised to 23.00 yen per share. This is an increase from the previous forecast of 21.00 yen, with the full-year dividend projected at 49.00 yen.
Read more -
Notice Regarding Completion of Exercise of the 2nd Series Stock Acquisition Rights Issued by Third-Party Allotment
On March 11, 2026, all 16,500 units of the 2nd series stock acquisition rights of Fuji Pharmaceutical Industries Ltd. were exercised, completing fundraising of 3.3 billion yen.
Read more
Latest News (5 items)
-
Average Analyst Rating: none
Average Target Price: ¥2,950
Rating Score: 2.00 (Based on 2 analysts)
※1=Strong Buy, 5=Strong Sell
Company Information
About
Fuji Pharma Co., Ltd. engages in the research and development, manufacture, and marketing of pharmaceutical products in Japan and internationally. The company offers injection agents, internal drugs, drugs for external use, and diagnostic products. It also provides medical care for women, in vitro diagnostics, acute medical care products, and curative medicines, and information regarding pharmaceuticals and health services, as well as contract manufacturing services. Fuji Pharma Co., Ltd. was incorporated in 1965 and is headquartered in Tokyo, Japan.
